Major gaps in online info for patients about AI and cancer
Reports and Proceedings
Updates every hour. Last Updated: 30-Oct-2026 21:16 ET (31-Oct-2026 01:16 GMT/UTC)
A team led by researchers from the National Center for Tumor Diseases (NCT/UCC) in Dresden at the Carl Gustav Carus University Hospital (UKD) and the Carl Gustav Carus Faculty of Medicine at the TUD Dresden University of Technology will present clinical results for the first time on May 31, 2026, at this year’s annual meeting of the American Society of Clinical Oncology (ASCO) regarding a new cancer immunotherapy for the treatment of advanced tumors. The results show overall good tolerability and clear signs of effectiveness of this novel immunotherapy. They are published in the renowned scientific journal Nature Medicine.
Fe-N-C interfacial engineering on commercial Pt/C catalysts, via unique 5d-3d/2p orbital hybridization, enables a breakthrough in fuel cell durability and performance. The engineered PtFe/C@Fe-N-C catalyst maintains 97.3% of its activity after 30,000 accelerated stress cycles. This exceptional stability and its high mass activity decisively surpass both the performance of pristine Pt/C and the U.S. Department of Energy's 2025 technical targets.